Why identity verification is vital during stability pulls:

In long-term stability programs—especially those involving multiple products or packaging types—sample mix-ups or labeling errors can easily occur. Such mistakes undermine data reliability and expose the organization to serious compliance risks. Near-infrared (NIR) spectroscopy offers a fast, non-destructive, and validated method to verify product identity before performing analytical tests. Integrating NIR at each stability pull ensures that the correct sample is being tested, improving the reliability of your entire stability program.

Consequences of identity errors in stability studies:

Without product-level identity checks:

• Incorrect data may be attributed to the wrong batch or product
• OOS/OOT investigations may be misdirected or inconclusive
• Regulatory inspections could uncover gaps in sample traceability
• Products may be approved or rejected based on faulty datasets

Using NIR allows for routine identity assurance without damaging the sample or delaying the test cycle.

Regulatory and Technical Context:

ICH and WHO guidance on product traceability and integrity:

ICH Q1A(R2) and WHO TRS 1010 require that each sample analyzed during stability testing be traceable to its source, properly labeled, and stored under the correct conditions. While traditional documentation helps, NIR adds an analytical safeguard. It enables quick confirmation of formulation presence and composition before initiating any critical assay or impurity tests. Regulatory filings benefit from such verification, and CTD Module 3.2.P.8.3 can reference NIR checks as part of the identity and integrity assurance process.

Audit expectations regarding identity verification:

Inspectors frequently check how stability samples are verified at the time of testing—especially in high-throughput labs or multi-site operations. Lack of analytical identity checks may result in observations, particularly if discrepancies are found in data or documentation. NIR provides a layer of proactive control that supports 21 CFR Part 11 compliance and GMP expectations.

Best Practices and Implementation:

Establish NIR methods specific to your product formulation:

Develop and validate NIR methods that can distinguish:

• Active pharmaceutical ingredient (API) fingerprint spectra
• Excipient-specific spectral zones
• Product-specific profiles (including for fixed-dose combinations)

Create a spectral reference library for all stability batches and ensure the method is validated per ICH Q2(R2) standards for identity specificity and spectral match acceptance criteria.

Integrate NIR checks into the stability workflow:

Before conducting any assay, dissolution, or impurity test:

• Perform a rapid NIR scan using a handheld or benchtop analyzer
• Compare the spectrum to the validated reference and calculate spectral match index (SMI)
• Approve for testing only if SMI falls within pre-defined thresholds (e.g., ≥ 0.95)

Log results into your LIMS or electronic stability workbook, with analyst initials and timestamps for traceability.

Use NIR data for investigation and lifecycle documentation:

In case of any discrepancy:

• Re-scan the sample to confirm potential mix-up or degradation
• Use the NIR data to support deviation investigation
• Document all identity checks as part of your stability summary files

NIR-based checks provide confidence to auditors and regulators that each time point was sampled and tested appropriately.

Incorporating NIR-based identity confirmation at each stability time point adds a smart layer of compliance, reduces errors, and demonstrates analytical maturity—making your pharmaceutical quality system both stronger and more audit-ready.